Johnson & Johnson (NYSE:JNJ) Stock Position Lowered by Lifeworks Advisors LLC

Lifeworks Advisors LLC decreased its stake in Johnson & Johnson (NYSE:JNJ) by 2.2% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 42,897 shares of the company’s stock after selling 959 shares during the quarter. Johnson & Johnson makes up about 1.4% of Lifeworks Advisors LLC’s holdings, making the stock its 11th biggest position. Lifeworks Advisors LLC’s holdings in Johnson & Johnson were worth $6,952,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Intelligence Driven Advisers LLC purchased a new stake in Johnson & Johnson in the 3rd quarter worth approximately $243,000. Tokio Marine Asset Management Co. Ltd. lifted its position in Johnson & Johnson by 5.4% in the 3rd quarter. Tokio Marine Asset Management Co. Ltd. now owns 66,313 shares of the company’s stock worth $10,747,000 after buying an additional 3,392 shares in the last quarter. Metis Global Partners LLC lifted its position in Johnson & Johnson by 3.2% in the 3rd quarter. Metis Global Partners LLC now owns 138,758 shares of the company’s stock worth $22,487,000 after buying an additional 4,283 shares in the last quarter. Curi RMB Capital LLC lifted its position in Johnson & Johnson by 2.2% in the 3rd quarter. Curi RMB Capital LLC now owns 104,083 shares of the company’s stock worth $16,868,000 after buying an additional 2,239 shares in the last quarter. Finally, Planning Capital Management Corp lifted its position in Johnson & Johnson by 1.0% in the 3rd quarter. Planning Capital Management Corp now owns 30,124 shares of the company’s stock worth $4,882,000 after buying an additional 309 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insider Transactions at Johnson & Johnson

In other news, VP Robert J. Decker sold 5,635 shares of the firm’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $165.06, for a total transaction of $930,113.10. Following the completion of the transaction, the vice president now directly owns 18,973 shares of the company’s stock, valued at approximately $3,131,683.38. This trade represents a 22.90 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.16% of the stock is owned by insiders.

Analysts Set New Price Targets

JNJ has been the topic of a number of recent research reports. Daiwa Capital Markets downgraded shares of Johnson & Johnson from an “outperform” rating to a “neutral” rating and cut their price target for the company from $160.00 to $150.00 in a report on Tuesday, July 23rd. Citigroup raised their price target on shares of Johnson & Johnson from $180.00 to $185.00 and gave the company a “buy” rating in a report on Wednesday, October 16th. Royal Bank of Canada raised their price target on shares of Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a report on Wednesday, October 16th. Daiwa America downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 23rd. Finally, Wells Fargo & Company raised their price target on shares of Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a report on Wednesday, October 16th. Seven equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $175.00.

Johnson & Johnson Stock Performance

NYSE JNJ opened at $151.86 on Friday. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. The firm has a market capitalization of $365.62 billion, a price-to-earnings ratio of 21.98, a P/E/G ratio of 2.72 and a beta of 0.53. The company’s fifty day moving average is $161.82 and its two-hundred day moving average is $155.99. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $168.85.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.21 by $0.21. The company had revenue of $22.47 billion for the quarter, compared to analyst estimates of $22.17 billion. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The business’s quarterly revenue was up 5.2% on a year-over-year basis. During the same period last year, the business posted $2.66 EPS. Equities research analysts forecast that Johnson & Johnson will post 9.93 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be issued a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.27%. The ex-dividend date of this dividend is Tuesday, November 26th. Johnson & Johnson’s payout ratio is 71.78%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.